Prognosis of Stage III Colorectal Carcinomas with FOLFOX Adjuvant Chemotherapy can be Predicted by Molecular Subtype

ABSTRACT: Comparison the mRNA expression profiles of 101 CRC tissues to those from matched 35 non-neoplastic colon mucosal tissues from patients with stage III CRCs treated with FOLFOX adjuvant chemotherapy in each molecular subtype. Gene expression–based subtyping is widely accepted as a relevant source of disease stratification. Results provide important information of molecular marker genes for molecular classification.

ORGANISM(S): Homo sapiens

PROVIDER: GSE83889 | GEO | 2017/05/31

SECONDARY ACCESSION(S): PRJNA327262

REPOSITORIES: GEO